摘要: |
目的:探讨mTOR抑制剂依维莫司治疗晚期血管肉瘤的临床疗效及安全性。方法:收集2013年11月至2018年9月采用依维莫司初治的5例晚期血管肉瘤患者的临床资料,观察并分析疗效与不良反应情况。结果:4例晚期血管肉瘤患者经依维莫司治疗数天后症状缓解,病灶缩小;1例阿帕替尼耐药的晚期血管肉瘤患者对依维莫司无反应,病情进展。依维莫司治疗不良反应主要为口腔溃疡,其中2例患者2级、3例患者1级。结论:依维莫司初治晚期血管肉瘤起效快,疗效较好,不良反应可控,值得进一步研究 |
关键词: 血管肉瘤 依维莫司 初治 不良反应 |
DOI:10.12025/j.issn.1008-6358.2019.20190041 |
分类号:R 732.2 |
基金项目: |
|
Efficacy and safety of everolimus in treatment of advanced angiosarcoma |
李智勇, 张秀萍, 张世龙, 许建芳, 王志明, 周宇红
|
|
Abstract: |
Objective:To investigate the efficacy and safety of mTOR inhibitor everolimus in the treatment of advanced angiosarcoma. Methods:Clinical data of 5 patients with advanced angiosarcoma initially treated with everolimus from November 2013 to September 2018 were collected to observe the efficacy and adverse reactions. Results:The symptoms of 4 patients with advanced angiosarcoma were relieved and the lesions narrowed within a few days after the treatment of everolimus. One patient with advanced angiosarcoma who was resistant to apatinib continued to progress. The main adverse effects of everolimus were oral ulcers, of which 2 cases were grade 2 and 3 cases were grade 1. Conclusions:Everolimus is effective in the treatment of advanced angiosarcoma with rapid onset of action and controllable adverse effects. |
Key words: angiosarcoma everolimus initial treatment adverse effects |